Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04965493




Registration number
NCT04965493
Ethics application status
Date submitted
15/07/2021
Date registered
16/07/2021

Titles & IDs
Public title
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Scientific title
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Secondary ID [1] 0 0
J2N-OX-JZNO
Secondary ID [2] 0 0
LOXO-BTK-20022
Universal Trial Number (UTN)
Trial acronym
BRUIN CLL-322
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Lymphocytic Leukemia 0 0
Small Lymphocytic Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Pirtobrutinib
Treatment: Drugs - Venetoclax
Treatment: Drugs - Rituximab

Experimental: Arm A (PVR) - Fixed duration pirtobrutinib in combination with venetoclax and rituximab

Active comparator: Arm B (VR) - Venetoclax with rituximab


Treatment: Drugs: Pirtobrutinib
Oral

Treatment: Drugs: Venetoclax
Oral

Treatment: Drugs: Rituximab
Intravenous (IV)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
To evaluate progression-free survival (PFS) of pirtobrutinib plus venetoclax and rituximab (Arm A) compared to venetoclax and rituximab (Arm B)
Timepoint [1] 0 0
Up to approximately 5 years
Secondary outcome [1] 0 0
To evaluate the efficacy of Arm A compared to Arm B: Progression-free survival (PFS)
Timepoint [1] 0 0
Up to approximately 5 years
Secondary outcome [2] 0 0
To evaluate the efficacy of Arm A compared to Arm B: Overall survival (OS)
Timepoint [2] 0 0
Up to approximately 5 years
Secondary outcome [3] 0 0
To evaluate the efficacy of Arm A compared to Arm B: Time to next treatment (TTNT)
Timepoint [3] 0 0
Up to approximately 5 years
Secondary outcome [4] 0 0
To evaluate the efficacy of Arm A compared to Arm B: Event-free survival (EFS)
Timepoint [4] 0 0
Up to approximately 5 years
Secondary outcome [5] 0 0
To evaluate the efficacy of Arm A compared to Arm B: Overall response rate (ORR)
Timepoint [5] 0 0
Up to approximately 5 years
Secondary outcome [6] 0 0
To evaluate the efficacy of Arm A compared to Arm B in patient-reported disease-related symptoms
Timepoint [6] 0 0
Up to approximately 5 years
Secondary outcome [7] 0 0
To evaluate the efficacy of Arm A compared to Arm B in patient-reported physical functioning
Timepoint [7] 0 0
Up to approximately 5 years

Eligibility
Key inclusion criteria
* Confirmed diagnosis of CLL/SLL requiring therapy per iwCLL 2018 criteria
* Previous treatment with at least one line of therapy that may include a covalent Bruton's tyrosine kinase (BTK) inhibitor
* Platelets greater than or equal to (=)50 x 10?/liter (L), hemoglobin =8 grams/deciliter (g/dL) and absolute neutrophil count =1.0 x 10?/L
* Adequate organ function
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
* Estimated creatinine clearance =30 milliliters per minute (mL/min)
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Known or suspected Richter's transformation at any time preceding enrollment
* Prior therapy with a non-covalent (reversible) BTK inhibitor
* Patients requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist
* Current treatment with strong cytochrome P450 (CYP) 3A4 (CYP3A4) inhibitors or inducers
* Prior therapy with venetoclax
* Central nervous system (CNS) involvement
* Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
* Known human immunodeficiency virus (HIV) infection, regardless of cluster of differentiation 4 (CD4) count
* Allogeneic stem cell transplantation (SCT) or chimeric antigen receptor (CAR)-T within 60 days
* Active hepatitis B or hepatitis C
* Known active cytomegalovirus (CMV) infection
* Uncontrolled immune thrombocytopenic purpura (ITP) or autoimmune hemolytic anemia (AIHA)
* Significant cardiovascular disease
* Vaccination with a live vaccine within 28 days prior to randomization
* Patients with the following hypersensitivity:

* Known hypersensitivity to any component or excipient of pirtobrutinib and venetoclax
* Prior significant hypersensitivity to rituximab
* Known allergy to allopurinol and inability to take uric acid lowering agent

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
20/09/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/01/2027
Actual
Sample size
Target
600
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,TAS,VIC,WA
Recruitment hospital [1] 0 0
Border Medical Oncology - Albury
Recruitment hospital [2] 0 0
Concord Repatriation General Hospital - Concord
Recruitment hospital [3] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [4] 0 0
Flinders Medical Centre - Adelaide
Recruitment hospital [5] 0 0
Royal Hobart Hospital - Hobart
Recruitment hospital [6] 0 0
St. Vincent's Hospital - Fitzroy
Recruitment hospital [7] 0 0
Peninsula Private Hospital - Frankston
Recruitment hospital [8] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [9] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment hospital [10] 0 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment postcode(s) [1] 0 0
2640 - Albury
Recruitment postcode(s) [2] 0 0
2139 - Concord
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
5042 - Adelaide
Recruitment postcode(s) [5] 0 0
7000 - Hobart
Recruitment postcode(s) [6] 0 0
3065 - Fitzroy
Recruitment postcode(s) [7] 0 0
3199 - Frankston
Recruitment postcode(s) [8] 0 0
3004 - Melbourne
Recruitment postcode(s) [9] 0 0
6150 - Murdoch
Recruitment postcode(s) [10] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Iowa
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Minnesota
Country [14] 0 0
United States of America
State/province [14] 0 0
Missouri
Country [15] 0 0
United States of America
State/province [15] 0 0
New Jersey
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Oklahoma
Country [20] 0 0
United States of America
State/province [20] 0 0
Oregon
Country [21] 0 0
United States of America
State/province [21] 0 0
Pennsylvania
Country [22] 0 0
United States of America
State/province [22] 0 0
Tennessee
Country [23] 0 0
United States of America
State/province [23] 0 0
Texas
Country [24] 0 0
United States of America
State/province [24] 0 0
Virginia
Country [25] 0 0
United States of America
State/province [25] 0 0
Washington
Country [26] 0 0
United States of America
State/province [26] 0 0
Wisconsin
Country [27] 0 0
Belgium
State/province [27] 0 0
Gent
Country [28] 0 0
Belgium
State/province [28] 0 0
Haine-Saint-Paul
Country [29] 0 0
Belgium
State/province [29] 0 0
Yvoir
Country [30] 0 0
Canada
State/province [30] 0 0
Alberta
Country [31] 0 0
Canada
State/province [31] 0 0
British Columbia
Country [32] 0 0
Canada
State/province [32] 0 0
Manitoba
Country [33] 0 0
Canada
State/province [33] 0 0
Ontario
Country [34] 0 0
Canada
State/province [34] 0 0
Quebec
Country [35] 0 0
China
State/province [35] 0 0
Anhui
Country [36] 0 0
China
State/province [36] 0 0
Beijing
Country [37] 0 0
China
State/province [37] 0 0
Fujian
Country [38] 0 0
China
State/province [38] 0 0
Guangdong
Country [39] 0 0
China
State/province [39] 0 0
Guangxi
Country [40] 0 0
China
State/province [40] 0 0
Henan
Country [41] 0 0
China
State/province [41] 0 0
Hubei
Country [42] 0 0
China
State/province [42] 0 0
Hunan
Country [43] 0 0
China
State/province [43] 0 0
Inner Mongolia
Country [44] 0 0
China
State/province [44] 0 0
Jiangsu
Country [45] 0 0
China
State/province [45] 0 0
Jiangxi
Country [46] 0 0
China
State/province [46] 0 0
Liaoning
Country [47] 0 0
China
State/province [47] 0 0
Nanjing
Country [48] 0 0
China
State/province [48] 0 0
Shandong
Country [49] 0 0
China
State/province [49] 0 0
Shanghai
Country [50] 0 0
China
State/province [50] 0 0
Tianjin
Country [51] 0 0
China
State/province [51] 0 0
Xicheng District
Country [52] 0 0
China
State/province [52] 0 0
Yunnan
Country [53] 0 0
China
State/province [53] 0 0
Zhejiang
Country [54] 0 0
China
State/province [54] 0 0
Chongqing
Country [55] 0 0
Czechia
State/province [55] 0 0
Brno
Country [56] 0 0
Czechia
State/province [56] 0 0
Hradec Kralove
Country [57] 0 0
Czechia
State/province [57] 0 0
Praha 10
Country [58] 0 0
Czechia
State/province [58] 0 0
Praha 2
Country [59] 0 0
Denmark
State/province [59] 0 0
Copenhagen
Country [60] 0 0
France
State/province [60] 0 0
Bas Rhin
Country [61] 0 0
France
State/province [61] 0 0
Cedex 13
Country [62] 0 0
France
State/province [62] 0 0
Cedex 1
Country [63] 0 0
France
State/province [63] 0 0
Cedex 9
Country [64] 0 0
France
State/province [64] 0 0
Cedex
Country [65] 0 0
France
State/province [65] 0 0
France Cédex
Country [66] 0 0
France
State/province [66] 0 0
Herault
Country [67] 0 0
France
State/province [67] 0 0
Paris
Country [68] 0 0
France
State/province [68] 0 0
Seine-Maritime
Country [69] 0 0
France
State/province [69] 0 0
Tours Cedex 9
Country [70] 0 0
France
State/province [70] 0 0
Vienne
Country [71] 0 0
France
State/province [71] 0 0
Le Mans
Country [72] 0 0
France
State/province [72] 0 0
Vandœuvre-lès-Nancy
Country [73] 0 0
Germany
State/province [73] 0 0
Bayern
Country [74] 0 0
Germany
State/province [74] 0 0
Mecklenburg Vorpommern
Country [75] 0 0
Germany
State/province [75] 0 0
Nordrhein Westfalen
Country [76] 0 0
Germany
State/province [76] 0 0
Rheinland Pfalz
Country [77] 0 0
Germany
State/province [77] 0 0
Sachsen
Country [78] 0 0
Germany
State/province [78] 0 0
Schleswig-Holstein
Country [79] 0 0
Germany
State/province [79] 0 0
Berlin
Country [80] 0 0
Germany
State/province [80] 0 0
Essen
Country [81] 0 0
Germany
State/province [81] 0 0
Würzburg
Country [82] 0 0
Hungary
State/province [82] 0 0
Budapest
Country [83] 0 0
Hungary
State/province [83] 0 0
Debrecen
Country [84] 0 0
Hungary
State/province [84] 0 0
Kaposvar
Country [85] 0 0
Ireland
State/province [85] 0 0
Dublin
Country [86] 0 0
Ireland
State/province [86] 0 0
Waterford
Country [87] 0 0
Israel
State/province [87] 0 0
Haifa
Country [88] 0 0
Israel
State/province [88] 0 0
Naharia
Country [89] 0 0
Israel
State/province [89] 0 0
Petah-Tikva
Country [90] 0 0
Israel
State/province [90] 0 0
Re?ovot
Country [91] 0 0
Israel
State/province [91] 0 0
Tel Aviv
Country [92] 0 0
Italy
State/province [92] 0 0
Bologna
Country [93] 0 0
Italy
State/province [93] 0 0
Catanzaro
Country [94] 0 0
Italy
State/province [94] 0 0
Cona
Country [95] 0 0
Italy
State/province [95] 0 0
Cuneo
Country [96] 0 0
Italy
State/province [96] 0 0
Firenze
Country [97] 0 0
Italy
State/province [97] 0 0
Meldola
Country [98] 0 0
Italy
State/province [98] 0 0
Milano
Country [99] 0 0
Italy
State/province [99] 0 0
Modena
Country [100] 0 0
Italy
State/province [100] 0 0
Novara
Country [101] 0 0
Italy
State/province [101] 0 0
Roma
Country [102] 0 0
Italy
State/province [102] 0 0
Torino
Country [103] 0 0
Japan
State/province [103] 0 0
Aichi-Ken
Country [104] 0 0
Japan
State/province [104] 0 0
Aichi
Country [105] 0 0
Japan
State/province [105] 0 0
Hokkaido
Country [106] 0 0
Japan
State/province [106] 0 0
Kanagawa
Country [107] 0 0
Japan
State/province [107] 0 0
Kochi
Country [108] 0 0
Japan
State/province [108] 0 0
Kyoto
Country [109] 0 0
Japan
State/province [109] 0 0
Miyagi
Country [110] 0 0
Japan
State/province [110] 0 0
Osaka
Country [111] 0 0
Japan
State/province [111] 0 0
Saitama-Ken
Country [112] 0 0
Japan
State/province [112] 0 0
Tokyo
Country [113] 0 0
Japan
State/province [113] 0 0
Yamanshi
Country [114] 0 0
Japan
State/province [114] 0 0
Chiba-Ken
Country [115] 0 0
Japan
State/province [115] 0 0
Fukui
Country [116] 0 0
Japan
State/province [116] 0 0
Kumamoto
Country [117] 0 0
Japan
State/province [117] 0 0
Niigata
Country [118] 0 0
Japan
State/province [118] 0 0
Okayama
Country [119] 0 0
Japan
State/province [119] 0 0
Tokyo-To
Country [120] 0 0
Korea, Republic of
State/province [120] 0 0
Seoul-teukbyeolsi [Seoul]
Country [121] 0 0
Korea, Republic of
State/province [121] 0 0
Seoul
Country [122] 0 0
Poland
State/province [122] 0 0
Kujawsko-pomorskie
Country [123] 0 0
Poland
State/province [123] 0 0
Pomorskie
Country [124] 0 0
Poland
State/province [124] 0 0
Katowice
Country [125] 0 0
Poland
State/province [125] 0 0
Krakow
Country [126] 0 0
Poland
State/province [126] 0 0
Lublin
Country [127] 0 0
Poland
State/province [127] 0 0
Warszawa
Country [128] 0 0
Poland
State/province [128] 0 0
Lódz
Country [129] 0 0
Puerto Rico
State/province [129] 0 0
San Juan
Country [130] 0 0
Singapore
State/province [130] 0 0
Singapore
Country [131] 0 0
Spain
State/province [131] 0 0
Asturias
Country [132] 0 0
Spain
State/province [132] 0 0
Barcelona [Barcelona]
Country [133] 0 0
Spain
State/province [133] 0 0
Castilla La Mancha
Country [134] 0 0
Spain
State/province [134] 0 0
Madrid
Country [135] 0 0
Spain
State/province [135] 0 0
Malaga
Country [136] 0 0
Spain
State/province [136] 0 0
Mandrid
Country [137] 0 0
Spain
State/province [137] 0 0
Pozuelo De Alarcón
Country [138] 0 0
Spain
State/province [138] 0 0
Barcelona
Country [139] 0 0
Spain
State/province [139] 0 0
Sevilla
Country [140] 0 0
Spain
State/province [140] 0 0
Valencia
Country [141] 0 0
Sweden
State/province [141] 0 0
Lund
Country [142] 0 0
Sweden
State/province [142] 0 0
Stockholm
Country [143] 0 0
Sweden
State/province [143] 0 0
Uppsala
Country [144] 0 0
Switzerland
State/province [144] 0 0
Ticino
Country [145] 0 0
Switzerland
State/province [145] 0 0
Luzern
Country [146] 0 0
Taiwan
State/province [146] 0 0
Taoyuan City
Country [147] 0 0
Taiwan
State/province [147] 0 0
Taipei
Country [148] 0 0
United Kingdom
State/province [148] 0 0
Devon
Country [149] 0 0
United Kingdom
State/province [149] 0 0
England
Country [150] 0 0
United Kingdom
State/province [150] 0 0
West Midlands
Country [151] 0 0
United Kingdom
State/province [151] 0 0
West Yorkshire
Country [152] 0 0
United Kingdom
State/province [152] 0 0
Oxford
Country [153] 0 0
United Kingdom
State/province [153] 0 0
Surrey

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Loxo Oncology, Inc.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Eli Lilly and Company
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Patient Advocacy
Address 0 0
Country 0 0
Phone 0 0
1-855-LOXO-305
Fax 0 0
Email 0 0
clinicaltrials@loxooncology.com
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT04965493